Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | CPA2 | P48052 | 1/20 | 0.45 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14370014 | 0.90 | CASP1 (0.60) | CASP1BACE1BACE2OPRD1GRIA1 | |
| SCHEMBL5689768 | 0.89 | CASP1 (0.59) | CASP1BACE1BACE2OPRD1GRIA1 | |
| SCHEMBL2314756 | 0.89 | CASP1 (0.61) | CASP1BACE1BACE2OPRD1GRIA1 | |
| SCHEMBL2314769 | 0.89 | CASP1 (0.61) | CASP1BACE1BACE2OPRD1GRIA1 | |
| SCHEMBL24520152 | 0.87 | BACE1 (0.58) | CASP1BACE1BACE2ACE | |
| SCHEMBL30493755 | 0.85 | ACE (0.56) | CASP1BACE1BACE2OPRD1GRIA1 | |
| SCHEMBL29611561 | 0.85 | BACE1 (0.58) | CASP1BACE1BACE2OPRD1ACE | |
| SCHEMBL30863540 | 0.85 | CASP1 (0.52) | CASP1BACE1BACE2OPRD1GRIA1 | |
| SCHEMBL23600925 | 0.84 | ACE (0.55) | CASP1BACE1BACE2ACE | |
| SCHEMBL23572631 | 0.84 | ACE (0.55) | CASP1BACE1BACE2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | GENERATION BIO CO. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | STING1, DCLRE1B, DCLRE1A | CASP1 180/4885BACE1 3302/4885BACE2 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.